Latham & Watkins LLP represented the underwriters in the transaction. Castle Biosciences, Inc. closed its underwritten public offering of 4,600,000 shares of its common stock, including…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
